1. Home
  2. FEMY vs SNGX Comparison

FEMY vs SNGX Comparison

Compare FEMY & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEMY
  • SNGX
  • Stock Information
  • Founded
  • FEMY 2004
  • SNGX 1987
  • Country
  • FEMY United States
  • SNGX United States
  • Employees
  • FEMY N/A
  • SNGX N/A
  • Industry
  • FEMY Medical/Dental Instruments
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FEMY Health Care
  • SNGX Health Care
  • Exchange
  • FEMY Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • FEMY 12.5M
  • SNGX 10.1M
  • IPO Year
  • FEMY 2021
  • SNGX 1987
  • Fundamental
  • Price
  • FEMY $0.36
  • SNGX $2.81
  • Analyst Decision
  • FEMY Strong Buy
  • SNGX Strong Buy
  • Analyst Count
  • FEMY 3
  • SNGX 1
  • Target Price
  • FEMY $7.33
  • SNGX $6.00
  • AVG Volume (30 Days)
  • FEMY 2.9M
  • SNGX 659.7K
  • Earning Date
  • FEMY 11-11-2025
  • SNGX 11-07-2025
  • Dividend Yield
  • FEMY N/A
  • SNGX N/A
  • EPS Growth
  • FEMY N/A
  • SNGX N/A
  • EPS
  • FEMY N/A
  • SNGX N/A
  • Revenue
  • FEMY $1,887,016.00
  • SNGX N/A
  • Revenue This Year
  • FEMY $103.55
  • SNGX N/A
  • Revenue Next Year
  • FEMY $148.13
  • SNGX N/A
  • P/E Ratio
  • FEMY N/A
  • SNGX N/A
  • Revenue Growth
  • FEMY 98.61
  • SNGX N/A
  • 52 Week Low
  • FEMY $0.31
  • SNGX $1.09
  • 52 Week High
  • FEMY $1.80
  • SNGX $6.23
  • Technical
  • Relative Strength Index (RSI)
  • FEMY 28.31
  • SNGX 49.49
  • Support Level
  • FEMY $0.35
  • SNGX $2.58
  • Resistance Level
  • FEMY $0.40
  • SNGX $2.98
  • Average True Range (ATR)
  • FEMY 0.04
  • SNGX 0.19
  • MACD
  • FEMY 0.01
  • SNGX -0.07
  • Stochastic Oscillator
  • FEMY 5.20
  • SNGX 35.94

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: